News
Roche’s combination breast cancer treatment delivers positive results
Roche, the Breast International Group, Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation have announced updated data from the phase 3 APHINITY study into HER2-positive early breast cancer.